A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, cardiovascular disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1	2026-06-04		NCT07255898

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.	110
Sichuan Baili Pharmaceutical Co., Ltd.	135

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
West China Hospital of Sichuan University	Chengdu	China	68